AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Toronto Dominion Bank

Toronto Dominion Bank lifted its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 51.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,080 shares of the company's stock after purchasing an additional 9,151 shares during the quarter. Toronto Dominion Bank's holdings in AstraZeneca were worth $1,774,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Banque Transatlantique SA acquired a new stake in shares of AstraZeneca in the fourth quarter valued at $26,000. CoreCap Advisors LLC boosted its stake in shares of AstraZeneca by 31.8% in the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock valued at $42,000 after buying an additional 155 shares during the period. Crews Bank & Trust purchased a new stake in shares of AstraZeneca in the 4th quarter valued at approximately $55,000. Golden State Wealth Management LLC acquired a new stake in shares of AstraZeneca in the 4th quarter valued at $55,000. Finally, Newbridge Financial Services Group Inc. purchased a new stake in shares of AstraZeneca during the 4th quarter worth $55,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have issued reports on AZN shares. UBS Group raised AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. BNP Paribas initiated coverage on shares of AstraZeneca in a research note on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target on the stock. Finally, Morgan Stanley started coverage on AstraZeneca in a report on Wednesday, February 12th. They set an "overweight" rating on the stock. One research analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $88.00.

AstraZeneca Price Performance

Shares of NASDAQ:AZN traded up $0.55 during midday trading on Tuesday, hitting $70.96. 4,459,225 shares of the stock were exchanged, compared to its average volume of 5,181,264. The company has a 50 day moving average price of $69.66 and a 200-day moving average price of $69.56. The stock has a market cap of $220.07 billion, a P/E ratio of 31.40, a PEG ratio of 1.42 and a beta of 0.40. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The company had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. During the same quarter in the prior year, the company posted $2.06 EPS. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. On average, research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.